RESEARCH - Juvenile idiopathic arthritis: current and future treatment options

[Guest guest]

Expert Opin Pharmacother. 2006 Mar;7(4):387-99.

Juvenile idiopathic arthritis: current and future treatment options.

i G, Zulian F.

Department of Pediatric Rheumatology, University of Padua, Italy.

Juvenile idiopathic arthritis is the most common rheumatic disease in

children. The management of juvenile idiopathic arthritis has improved in

recent decades, and morbidity due to the disease is significantly decreased.

In particular, the use of more effective drugs and their combination has

changed the course of the disease in many patients. The increasing knowledge

of inflammation mechanisms has lead to the development of new agents that

target specific cytokines interfering with the inflammatory cascade. In

particular, anti-TNF agents seem effective: etanercept is the only one

licensed for juvenile idiopathic arthritis, and Phase III trials on two

other anti-TNF agents, infliximab and adalimumab, are ongoing. This review

discusses the current practice in the medical management of juvenile

idiopathic arthritis, and potential new agents are discussed.

PMID: 16503811

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve & db=pubmed & dopt=Abstra\

ct & list_uids=16503811

Not an MD

I'll tell you where to go!

Mayo Clinic in Rochester

http://www.mayoclinic.org/rochester

s Hopkins Medicine

http://www.hopkinsmedicine.org